AbbVie
ABBV
4,253 hedge funds and large institutions have $335B invested in AbbVie in 2026 Q2 according to their latest regulatory filings, with 287 funds opening new positions, 1,935 increasing their positions, 1,556 reducing their positions, and 112 closing their positions.
156% more first-time investments, than exits
New positions opened: 287 | Existing positions closed: 112
86% more capital inflows, than outflows
Capital inflows: $20.6B | Capital outflows: $11.1B
24% more repeat investments, than reductions
Existing positions increased: 1,935 | Existing positions reduced: 1,556
17% more call options, than puts
Call options by funds: $3.71B | Put options by funds: $3.17B
14% more funds holding in top 10
Funds holding in top 10: 175 → 200 (+25)
3% more funds holding
Funds holding: 4,129 → 4,253 (+124)
2.1% more ownership
Funds ownership: 73.42% → 75.53% (+2.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.16B |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$718M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$643M |
| 4 |
SG Americas Securities
New York
|
+$613M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$576M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$1.91B |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$581M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$403M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$396M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$353M |
ABBV Hedge Fund Activity: Q2 2026 in Review
4,253 of the 8,377 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2026, worth a combined $335B — up 19% from $282B a quarter earlier.
Buyers outnumbered sellers: 287 funds opened new ABBV positions and 112 closed out — a net gain of 175 holders — while 1,935 added to existing stakes and 1,556 trimmed.
The largest buyer was Franklin Resources, adding an estimated $1.16B. The largest seller was JP Morgan Chase, cutting an estimated $1.91B.
- 4,253 institutional investors held AbbVie (ABBV) as of Q2 2026, up from 4,129 in Q1 2026.
- Funds reported $335B of AbbVie stock for Q2 2026, up 19% quarter-over-quarter.
- 287 funds opened new AbbVie positions in Q2 2026 and 112 closed out, a net change of +175 holders.
- The largest AbbVie buyer in Q2 2026 was Franklin Resources, an estimated $1.16B added.
- The largest AbbVie seller in Q2 2026 was JP Morgan Chase, an estimated $1.91B sold.
Based on aggregated 13F filings for Q2 2026.